ReviewCroatian medical journal2011
Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
Review in Croatian medical journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Does external reference pricing deliver what it promises? Evidence on its impact at national level.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Pooled it
- Variations in external reference pricing implementation: does it matter for public policy?The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.Journal of pharmaceutical policy and practice · 2026Review
- An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- The impact of patent expiry on drug prices: insights from the Dutch market.Journal of market access & health policy · 2020Article
- Stakeholder opinions on value in healthcare.European journal of hospital pharmacy : science and practice · 2019Article
- Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry.Cardiology research and practice · 2018Article
- Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.Frontiers in public health · 2018Review
- Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.BMC health services research · 2017Article
- Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review.Frontiers in pharmacology · 2017Article
- Affordability of medicines in the European Union.PloS one · 2017Article
- Critical Appraisal of Reimbursement List in Bosnia and Herzegovina.Frontiers in pharmacology · 2017Article
- The Value of Medicines: A Crucial but Vague Concept.PharmacoEconomics · 2016Review
- Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.International journal for equity in health · 2015Article
- Distribution and trends in outpatient utilization of generic versus brand name psychopharmaceuticals during a ten-year period in Croatia.BMC health services research · 2014Article
- Market access of cancer drugs in European countries: improving resource allocation.Targeted oncology · 2014Review
- Medication use in European primary care patients with lower respiratory tract infection: an observational study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2014Observational
- Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna.Journal of pharmaceutical policy and practice · 2014Article
- The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices.Cost effectiveness and resource allocation : C/E · 2013Article
- Discounts and rebates granted to public payers for medicines in European countries.Southern med review · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo perform a comparative analysis of the pharmaceutical pricing and reimbursement systems in Croatia and the 27 European Union (EU) Member States.
methodsKnowledge about the pharmaceutical systems in Croatia and the 27 EU Member States was acquired by literature review and primary research with stakeholders.
resultsPharmaceutical prices are controlled at all levels in Croatia, which is also the case in 21 EU Member States. Like many EU countries, Croatia also applies external price referencing, i.e., compares prices with other countries. While the wholesale remuneration by a statutorily regulated linear mark-up is applied in Croatia and in several EU countries, the pharmacy compensation for dispensing reimbursable medicines in the form of a flat rate service fee in Croatia is rare among EU countries, which usually apply a linear or regressive pharmacy mark-up scheme. Like in most EU countries, the Croatian Social Insurance reimburses specific medicines at 100%, whereas patients are charged co-payments for other reimbursable medicines. Criteria for reimbursement include the medicine's importance from the public health perspective, its therapeutic value, and relative effectiveness. In Croatia and in many EU Member States, reimbursement is based on a reference price system.
conclusionThe Croatian pharmaceutical system is similar to those in the EU Member States. Key policies, like external price referencing and reference price systems, which have increasingly been introduced in EU countries are also applied in Croatia and serve the same purpose: to ensure access to medicines while containing public pharmaceutical expenditure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.